Raquel Piñeiro Pérez

Mrs. Raquel Piñeiro Pérez

Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Galicia, Spain
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RPRaquel Piñeiro Pérez
Raquel Piñeiro Pérez
MPMiguel Abal Posada
Miguel Abal Posada
LMLaura Muinelo
Laura Muinelo
Endometrial cancer (EC) is the most frequent gynecological cancer in developed countries and its incidence shows an increasing trend. Fortunately, the prognosis of the disease is good when the tumour is diagnosed in an early phase, but some patients recur after surgery and develop distant metastasis. The therapy options for EC for advanced disease are more limited than for other tumours. Therefore, the application of non-invasive strategies to anticipate the recurrence of localized tumours and guide the treatment in advanced stages represents a clear requirement to improve the survival and quality of life of patients with EC. To achieve this desired precision oncology, it is necessary to invest in the identification and validation of circulating markers that allow a more effective stratification and monitoring of patients. We here review the main advances made for the evaluation of circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), circulating extracellular vesicles (cEVs), and other non-invasive biomarkers as a monitoring tool in the context of localized and advanced endometrial tumours, with the aim of providing a global perspective of the achievements and the key areas in which the use of these markers can be developed into a real clinical tool.

Verified
Journal Article
Open access
PDF file
CCCarlos Casas-Arozamena
Carlos Casas-Arozamena
ACAlexandra Cortegoso
Alexandra Cortegoso
RPRaquel Piñeiro Pérez
Raquel Piñeiro Pérez
AAAlicia Abalo
Alicia Abalo
EAEfigenia Arias
Efigenia Arias
JCJuan Cueva
Juan Cueva
Endometrial cancer (EC) is the 4th most common neoplasm of the female genital tract, with 15–20% of patients being of high risk of recurrence which leads to a significant decrease in patient survival. Current therapeutic options for patients with EC are poor, being the combined therapy of carboplatin and paclitaxel the standard of care, with limited efficacy. Therefore, new therapeutic options and better monitoring tools are needed to improve the management of the disease. In the current case report, we showcase the value of liquid biopsy analyses in a microsatellite instability EC patient with initially good prognosis that however underwent rapid progression disease within 6 months post-surgery; through the study of plasma cfDNA/ctDNA dynamics to assess the tumour evolution during treatment, as well as the study of the uterine aspirate as a valuable sample that captures the intra-tumour heterogeneity that allows a comprehensive genomic profiling of the disease to identify potential therapeutic options. Furthermore, preclinical models were generated at the time of tumour progression to assess the efficacy of the identified targeted therapies.

22 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RPRaquel Piñeiro Pérez
Raquel Piñeiro Pérez
AVAna Vilar
Ana Vilar
EAEfigenia Arias
Efigenia Arias
VSVictoria Sampayo
Victoria Sampayo
AAAlicia Abalo-Piñeiro
Alicia Abalo-Piñeiro
LMLaura Muinelo
Laura Muinelo
Although the tumor immune microenvironment has been studied in endometrial cancer, the systemic immune alterations associated with disease progression and their potential prognostic significance remain poorly defined. In this study, peripheral blood immune subsets were characterized by multiparametric flow cytometry in 67 patients with EC and 20 healthy controls, including dendritic cells, MDSCs, T-cell subsets, NK cells, and exhaustion and senescence associated markers. Immune profiles were similar between healthy controls and patients with early-stage disease, whereas advanced tumors showed marked changes, including dendritic cell expansion, reduced CD4 + T-cell proportions, and increased frequencies of CD8 + CD27 - CD28 - and CD8 + CD57 + populations. Among clinicopathologic features, MDSC levels were associated with tumor grade and myometrial infiltration, while regulatory T cells were increased in TP53-mutated and microsatellite-stable tumors. In the advanced cohort (n=31), non-responders frequently displayed elevated CD8 + , CD8 + CD27 - CD28 - , and CD8 + CD57 + levels alongside decreased CD27 + CD28 + proportions. In multivariable Cox models, higher baseline CD8 + (HR 1.13), CD8 + CD27 - CD28 - (HR 1.04), and CD8 + CD57 + proportions (HR 1.07; all p<0.05) were independently associated with shorter PFS, whereas higher CD27 + CD28 + levels were associated with improved PFS. CD27 - CD28 - proportions were also linked to worse PFS by Kaplan-Meier analysis (HR 5.1, log-rank p=0.005). Longitudinal analysis (n=28) showed that senescent-like lymphocyte levels remained associated with progression across timepoints (OR 18.80), whereas total CD8 + proportions diverged progressively, reaching significance only from 6 months onward. Together, these findings identify systemic immune remodeling as a characteristic of advanced endometrial cancer and support the potential of circulating immune profiling for patient stratification and prognostic assessment, pending validation in larger prospective cohorts.

4 September 2026 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
RPRaquel Piñeiro Pérez
Raquel Piñeiro Pérez
AVAna Vilar
Ana Vilar
EAEfigenia Arias
Efigenia Arias
VSVictoria Sampayo
Victoria Sampayo
AAAlicia Abalo-Piñeiro
Alicia Abalo-Piñeiro
LMLaura Muinelo
Laura Muinelo